BACKGROUND: Dabigatran is a direct thrombin inhibitor approved by the FDA in October 2010 for the treatment of nonvalvular atrial fibrillation. Little is known regarding patient adherence to this therapy.
A trial fibrillation, the most common type of cardiac arrhythmia, affects 0.4%-1% of the general population. 1 The incidence of atrial fibrillation increases significantly with age. 1 Patients with atrial fibrillation have 4 to 5 times elevated risk for ischemic stroke, with higher risk among older adults. 2 In October 2010, dabigatran etexilate, a direct thrombin inhibitor, was approved by the U.S. Food and Drug Administration for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 3 This approval was based on the results of the RE-LY trial that demonstrated dabigatran to be noninferior to warfarin (vitamin K antagonist) in reducing stroke or systemic embolism. 4 Compared with warfarin, the mainstay anticoagulant therapy for over 50 years, dabigatran offers a more convenient anticoagulant therapy for patients and physicians. Dabigatran is administered at a fixed dose and does not require frequent lab monitoring or dose adjustments in order to avoid adverse events of bleeding or subtherapeutic dosing. However, the absence of any requirement for laboratory monitoring may lead to fewer clinical encounters during which the importance of adherence could be reinforced. 5 Moreover, dabigatran is administered twice daily rather than once daily, which could also lead to poorer adherence. 6 Less is known about adherence to novel oral anticoagulants, and what evidence that does exist suggests limited nonadherence to dabigatran, the first novel agent to be approved in clinical trials in the United States. [7] [8] [9] In the RE-LY trial, 15% of atrial fibrillation patients discontinued 150 mg dabigatran at 1 year and 21% discontinued at 2 years. 4 The RE-COVER trial, which evaluated dabigatran vs. warfarin for the treatment of acute venous thromboembolism, reported an adherence rate of 98%. 10 Adherence in clinical trials is typically higher than
• Dabigatran is a direct thrombin inhibitor approved by the FDA for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
• Dabigatran offers a convenient dosing regimen and does not require frequent laboratory monitoring of drug levels.
• Adherence rates have been as high as 85%-98% in clinical trials; limited studies have evaluated adherence in the real-world setting.
What is already known about this subject
• At 6 months of initiating dabigatran, the mean medication possession ratio (MPR) of prevalent atrial fibrillation patients is 0.73, and 2 in 5 dabigatran users had MPRs < 0.80. • The mean MPR and percentage of nonadherence (MPR < 0.80) decreased as the length of follow-up increased. At 1 year, the average MPR was 0.65, and 49.2% of patients failed to adhere to dabigatran (MPR < 0.80).
What this study adds study was either the last date of the follow-up period, withdrawal, death, or the end of the study. We restricted our primary analysis to individuals whose index date was after the date of diagnosis of atrial fibrillation; that is, prevalent atrial fibrillation patients who were only exposed to dabigatran during the entire follow-up period (nonswitchers). To compare adherence and persistence among patients with incident atrial fibrillation, we also identified incident cohorts by including those with a first diagnosis of atrial fibrillation after the index date in the secondary analysis. We identified the first date of diagnosis of atrial fibrillation for all subjects. Subjects eligible for the incident atrial fibrillation cohort had a diagnosis of atrial fibrillation after the index date and thus no diagnosis for atrial fibrillation over the 6-month baseline period. Furthermore, we identified those individuals who switched from dabigatran to warfarin or rivaroxaban during the follow-up period.
Study Measures and Analysis
Multiple time points were selected to quantify adherence and persistence over time. We derived 3 continuously enrolled patient cohorts with follow-up periods of 6 months, 9 months, and 12 months. Subjects included in the cohorts with longer follow-up periods were subsets of patients in the cohorts with shorter periods. We assessed patients' demographic characteristics prior to the index date, including age, gender, and region of residence. We calculated the CHADS 2 score, a validated clinical classification scheme used to predict the risk of stroke in atrial fibrillation patients by factoring in congestive heart failure, hypertension, age ≥ 75, diabetes mellitus, and prior stroke/ transient ischemic attack. 13 The CHADS 2 score was calculated using medical claims over the baseline period. Diagnoses of congestive heart failure, hypertension, diabetes mellitus, stroke, and transient ischemic attack were identified using ICD-9-CM codes. 14, 15 The ICD-9-CM codes are presented in the Appendix. We quantified adherence and persistence using pharmacy claims for dabigatran that were filled during the follow-up period. We measured adherence using the medication possession ratio (MPR), which we calculated as the total number of days with dispensed supply of dabigatran divided by the follow-up period (180 days, 270 days, or 365 days). Since patients may stockpile medications at home, overlaps between claims were allowed and were included in the calculation of the total number of days supply of dabigatran. This may result in a value for the MPR that is greater than 1; we capped the MPR at 1. We excluded any drug supply that covered the post-follow-up time from the analysis. We used a cutoff point of 0.80 to dichotomize individuals as adherent (MPR ≥ 0.80) or nonadherent (MPR < 0.80) as is standard in studies of adherence. 16 We characterized persistence by treatment discontinuation, defining individuals with gaps of 60 days or longer in dabigatran supply as failing to persist on their therapy. in usual practice due to selection of more highly motivated patients at baseline and greater monitoring and follow-up of trial participants. 11 We examined adherence and persistence to dabigatran among adults with nonvalvular atrial fibrillation in a real-world setting.
■■ Methods Data
We used data from the nationally representative IMS Health LifeLink Health Plan Claims Database. This dataset provides information on commercial health plan claims from managed care plans and other sources throughout the United States. The database includes information on inpatient and outpatient diagnoses in the format of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes and procedures in the format of Current Procedural Terminology (CPT-4) and Healthcare Common Procedure Coding System codes. Retail and mail-order prescription records, which include National Drug Code (NDC) numbers and quantity of dispensed medication, are all available. Dates of service for all claims, the charge allowed and paid amount of all claims, patient demographic characteristics (including age, gender, and geographic region where the patient resides), payer type (such as commercial, self-pay), health plan product type (such as health maintenance organization, preferred provider organization), provider specialty, and the start and end date of the enrollment are available.
Study Population
We included patients with prevalent atrial fibrillation who filled at least 1 prescription for dabigatran from October 1, 2010 through March 31, 2012. Patients with prevalent atrial fibrillation were identified as those who had an ICD-9-CM diagnosis code of 427.31 before the first date of filling a prescription for dabigatran (index date). Diagnoses of atrial fibrillation were recorded during the 6-month baseline period prior to the index date. This code had been validated in many studies and showed a positive predictive value (PPV) of 70%-96%. 12 Dabigatran use was identified using NDC numbers, which are provided in the Appendix (available in online article).
To be included in the cohort, individuals had to meet the following criteria: (a) aged 18 years and above on the index date; (b) continuous medical and pharmacy enrollment with benefits of 6 months prior to the index date; (c) no prescription claims of anticoagulants, including warfarin, dabigatran, or rivaroxaban, in the previous 6 months prior to the index date (new users); and (d) a prescription of dabigatran between October 1, 2010, and March 31, 2012. To be eligible for each specific follow-up cohort, patients had to have continuous full medical and pharmacy enrollment during the entire follow-up period. Patients who lacked full medical and pharmacy enrollment over the study period were excluded. The end date of the Sensitivity analysis using gaps of 15 days, 30 days, and 90 days were performed. Among patients who were nonpersistent with dabigatran, we calculated their time to discontinuation. For patients who were switched to a second anticoagulant (warfarin or rivaroxaban) from dabigatran during the followup period, we calculated the incidence of switching and time to switch to a second anticoagulant and their adherence to oral anticoagulants (including warfarin, dabigatran, or rivaroxaban). We used the statistical software SAS, version 9.3 (SAS Institute, Inc., Cary, NC) for all analyses, except the KaplanMeier curve was plotted using STATA, version 12.1 (Stata Corp, College Station, TX).
■■ Results Study Population
We identified 287,938 patients with nonvalvular atrial fibrillation, of whom 5,951 fulfilled our inclusion criteria for a dabigatran user and were potentially eligible for inclusion in the study. Figure 1 describes the process of sample selection. After we applied the inclusion criteria for continuous enrollment over the follow-up period and then separated prevalent and incident atrial fibrillation patients, we included 2,893 individuals with prevalent atrial fibrillation in the 6-month follow-up cohort; 1,713 individuals in the 9-month cohort; and 768 individuals in the 12-month follow-up cohort. Baseline characteristics of the prevalent cohorts are shown in Table 1 .
The average age of the study population was 63.0 years across all 3 cohorts and approximately two thirds to three fourths of patients were male.
Switching Patterns
Of prevalent atrial fibrillation patients treated with dabigatran with at least 6 months of follow-up, 93.8% (n = 2,713) used dabigatran as the only oral anticoagulant, whereas the remainder 6.2% (n = 180) filled prescriptions for at least 1 other oral anticoagulant during the follow-up period (Table 2) . Of patients who switched, 97.2% (n = 175) switched to warfarin, while 2.8% (n = 5) initiated rivaroxaban ( 23 Note: 12-month and 9-month cohorts were derived from the 6-month cohort. SE = standard error.
TABLE 1

Baseline Characteristics of Study Population
Adherence and Persistence For patients with prevalent atrial fibrillation using dabigatran alone (n = 2,713), the mean MPR was 0.73 (SE = 0.30). Fortyone percent (n = 1,120) were nonadherent with dabigatran, and 31.5% (n = 854) had gaps of 60 days or greater ( Table 4 ). The rates of nonadherence and nonpersistence increased with the follow-up period. Among those observed for 9 months who used dabigatran alone, mean MPR was 0.69 (SE = 0.33), while among those observed for 12 months, the mean MPR was 0.65 (SE = 0.35). Rates of nonadherence were 46.7% (n = 741) among the 9-month cohort and 49.2% (n = 338) among the 12-month cohort, whereas 48.0% (n = 763) of the 9-month cohort and 48.5% (n = 333) of the 12-month cohort had gaps of 60 days and greater during follow-up. Table 5 shows the baseline characteristics of adherent and nonadherent patients. Adherent subjects had higher average age and higher average CHADS 2 score at baseline in all 3 cohorts. A Kaplan-Meier survival curve showing patients' persistence over 12 months is shown in Figure 2 . Among those exposed to multiple anticoagulants (switchers ,  Table 3 ), the mean MPR for anticoagulants was 0.84 (SE = 0.21). Of all prevalent atrial fibrillation patients, 31.7% (n = 57) were nonadherent to anticoagulants within the 6-month follow-up period, while 21.1% (n = 38) who were nonpersistent had gaps of 60 days or greater. Similarly, the rate of nonadherence and nonpersistence increased with a longer follow-up period.
Rates of adherence and persistence were similar when analyses were limited to patients with incident atrial fibrillation (Tables 3 and 4) .
■■ Discussion
Using individual-level claims data from 2010 to 2012, we found a mean MPR of 0.73 among patients with prevalent atrial fibrillation using dabigatran within 6 months of initiating therapy. Using an 0.80 cutoff point, 2 in 5 new dabigatran users were nonadherent. On average, the adherent patients were of older age and had higher baseline risk for stroke. Mean MPRs 23 
MPR = medication possession ratio; SE = standard error.
TABLE 3
Adherence and Persistence Among Switchers (Used More than 1 Anticoagulant During the Follow-Up Period) of Atrial Fibrillation Patients
was the inability to exclude treatment discontinuation initiated by prescribers. In contrast to the prior studies, we focused on new users of anticoagulants and followed patients for up to 1 year, a longer period compared with the previous analyses. Moreover, our study involved a national sample of users larger than a single center investigation, which is more generalizable.
We assessed adherence to dabigatran for up to 1 year, which is clinically relevant since anticoagulation is recommended for longterm use among atrial fibrillation patients. 17, 18 This longer followup period also allowed us to identify increases in nonadherence and nonpersistence to dabigatran/anticoagulants over time. This has been identified as a problem for many chronic therapies, 19 including cardiovascular treatments, 20 and reflects one of the perennial challenges regarding adherence. For example, in a retrospective cohort study of nonvalvular atrial fibrillation patients aged 18 years and above, the percentages of patients with a PDC of 80% or greater for twice-daily metoprolol and carvedilol were 50% and 53%, respectively. 21 These proportions were higher (62% and 63%, respectively) for those who took metoprolol and carvedilol once daily. Future investigations to identify associated patient or physician characteristics that lead to discontinuation of therapy are needed.
Prior studies suggested that poor adherence to anticoagulant therapies was associated with poor clinical outcomes. For example, the IN-RANGE study, a prospective cohort study that followed patients at anticoagulation clinics, found a significant association between poor adherence to warfarin and underanticoagulation measured as the international normalized ratio (INR) less than the lower limit of the target range. 22 Future studies should explore the predictors of nonadherence and test interventions to improve adherence to novel anticoagulants. decreased and rates of nonadherence increased as the length of follow-up increased, with nearly half of new dabigatran users being nonadherent at 1 year. Approximately 6% of patients switched to other anticoagulants within 6 months, the majority of whom initiated warfarin. These findings are important because novel oral anticoagulants represent an important new treatment option for atrial fibrillation and, increasingly, other common and costly thromboembolic disorders, yet little is known about individuals' real-world adherence to these products.
At least 3 studies have examined adherence and persistence to dabigatran. [7] [8] [9] The first used data from a large pharmacy benefit manager and identified a nonpersistence rate of 40% (defined as a gap of 30 days or more in prescriptions) during 180-day follow-up period among patients with or without exposure to warfarin in the 180 days prior to initiating dabigatran. 7 Moreover, the study reported a mean proprortion of days covered (PDC) of 0.67 for the warfarin-naïve cohort (no exposure to warfarin within 180 days prior to initiating dabigatran). We observed a similar nonadherence rate (44.3%) and mean MPR (mean MPR = 0.73) in our study. The second investigation, which followed a group of dabigatran users at a single medical center by administering questionnaires, identified that 70% of 92 recruited patients remained on dabigatran over 3-12 months. 8 Another study evaluated adherence to dabigatran using medical and pharmacy records at a medical center and affiliated clinic. 9 Of all 159 eligible subjects, 43% had an MPR < 0.80 and the mean MPR was 0.63. Although this study measured adherence by prescriptions picked up at a local pharmacy and validated through orders of medical records, a different methodological approach from ours, the rate of nonadherence (MPR < 0.80) was similar to our findings. One possible explanation for the higher mean MPR observed in our study 
Limitations
Our study has some limitations. Although there are 3 novel oral anticoagulants available on the market, we limited our analyses to dabigatran since it was the first agent to receive U.S. market approval and the complicated dosing of warfarin precluded comparison of warfarin vs. dabigatran adherence. The data excluded some clinical variables of interest and thus do not allow for us to quantify the degree to which observed nonadherence was due to patient, physician, or health-system factors. In some cases, nonuse may have represented clinically appropriate treatment discontinuations due to adverse effects, such as bleeding. Our estimates presume that patients take all the medications they fill rather than stockpiling them, an assumption that is inherent within all adherence analyses using administrative claims data. Our analyses were limited to patients with continuous coverage and thus may underestimate the true rates of nonadherence among a broader population. Finally, as with most adherence studies that incorporate a measure of MPR, we used a conventional cutoff point of 0.80 to classify patients as adherent or not. The 
■■ Conclusions
Our findings suggest that 2 in 5 patients with atrial fibrillation may not adhere to dabigatran after 6 months, and up to one half of patients are poorly adherent 1 year out from the initiation of therapy. These findings were similar to those seen in prior analyses. [7] [8] [9] Given the importance of adherence to anticoagulation for the prevention and treatment of thromboembolism, future studies are needed to understand the underlying reasons for the observed nonadherence and how to mitigate them. Moreover, investigations of associations between adherence and relevant clinical outcomes are needed to fully understand the degree to which the safety and effectiveness of dabigatran and other novel oral anticoagulants are affected by such patterns of utilization.
